Nanoparticles can improve stroke recovery by enhancing brain stimulation : study
Pradip Mahajan Fri, 09/30/2022 - 16:45
In a recent study, researchers from Xi’an Jiaotong-Liverpool University and other universities in China have reported that brain stimulation combined with a nose spray containing nanoparticles can improve recovery after ischemic stroke in an animal model.
SEC recommends to grant permission to Biocon to conduct phase 2 trial for Itolizumab
Rajesh Vagh Fri, 09/30/2022 - 15:41
Subject Expert Committee of CDSCO recommends to grant permission to Biocon to conduct phase 2 clinical trial for Itolizumab for Injection (r-DNA origin) 100 mg per vial.
Amylyx Pharmaceuticals announces FDA approval of RELYVRIO for the Treatment of ALS
Pradip Mahajan Fri, 09/30/2022 - 15:35
Amylyx Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for the treatment of adults with amyotrophic lateral sclerosis (ALS). RELYVRIO (previously known as AMX0035 in the U.S.) significantly slowed the loss of physical function in people living with ALS in a randomized, placebo-controlled clinical trial. RELYVRIO can be taken as a monotherapy or with existing approved treatments.
Living donor transplantation offers a safe alternative for liver transplant patients
Pradip Mahajan Thu, 09/29/2022 - 16:24
Demand for donor livers for transplant patients outstrips supply with over 15% of waitlist patients dying after a year. A new international study offers support for increasing the use of living donor liver transplantation (LDLT) in Western countries and reducing the imbalance between organ supply and demand. This study is reported in the Journal of Hepatology, the official journal of the European Association for the Study of the Liver, published by Elsevier.
Fasting-Mimicking Diet Reduces Signs of Dementia in Mice
Pradip Mahajan Thu, 09/29/2022 - 16:20
Short cycles of a low-calorie diet that replicates fasting appeared to reduce inflammation and delay cognitive decline in mouse models of Alzheimer’s disease; initial data indicates diet’s safety in Alzheimer’s patients.
New Zika Vaccine Shows Promise in Animal Models
Pradip Mahajan Thu, 09/29/2022 - 16:16
Researchers from the University of California, Los Angeles (UCLA) have developed a Zika vaccine technology that is highly effective and safe in preclinical mouse models. In a pregnant mouse model, the vaccine prevented both the pregnant mothers and the developing fetuses from developing systemic infection. The research is published in Microbiology Spectrum, a journal of the American Society for Microbiology.
Mercks Keytruda gets Japanese approval
Pradip Mahajan Thu, 09/29/2022 - 16:12
Merck known as MSD outside of the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received four new approvals from Japan’s Ministry of Health, Labor and Welfare (MHLW)
Lupin receives warning letter from USFDA
Rajesh Vagh Thu, 09/29/2022 - 15:16
Lupin has received a warning letter from the USFDA for their Tarapur, Maharashtra facility. The U.S. FDA had inspected the Lupin Tarapur site from March 22, 2022 to April 4, 2022.
Initially, USFDA has closed the inspection at Lupin’s Tarapur manufacturing facility with four observations.
Lupin Launches Sildenafil for Oral Suspension in the United States
Pradip Mahajan Thu, 09/29/2022 - 15:08
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
Bayers Eylea approved in Japan for child ratinopathy
Pradip Mahajan Wed, 09/28/2022 - 14:21
Bayer announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Eylea (aflibercept) intravitreal injection 40 mg/mL for the treatment of preterm infants with retinopathy of prematurity (ROP).